HC Wainwright Reaffirms “Buy” Rating for X4 Pharmaceuticals (NASDAQ:XFOR)

HC Wainwright restated their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR) in a report issued on Friday, Benzinga reports. HC Wainwright currently has a $5.00 price objective on the stock.

Separately, Cantor Fitzgerald reaffirmed an overweight rating and set a $5.00 price objective on shares of X4 Pharmaceuticals in a research note on Friday, May 31st.

X4 Pharmaceuticals Stock Down 13.4 %

NASDAQ:XFOR opened at $0.58 on Friday. X4 Pharmaceuticals has a 12-month low of $0.57 and a 12-month high of $2.06. The company has a quick ratio of 3.71, a current ratio of 3.71 and a debt-to-equity ratio of 52.92. The firm has a market capitalization of $97.41 million, a P/E ratio of -0.83 and a beta of 0.40. The stock’s fifty day simple moving average is $1.02 and its 200-day simple moving average is $0.99.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Equities research analysts expect that X4 Pharmaceuticals will post -0.55 earnings per share for the current year.

Institutional Trading of X4 Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC increased its position in shares of X4 Pharmaceuticals by 38.8% in the fourth quarter. SG Americas Securities LLC now owns 47,668 shares of the company’s stock valued at $40,000 after acquiring an additional 13,328 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of X4 Pharmaceuticals by 46.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock valued at $55,000 after acquiring an additional 12,514 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of X4 Pharmaceuticals in the third quarter valued at about $678,000. Kingdon Capital Management L.L.C. increased its position in shares of X4 Pharmaceuticals by 76.0% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock valued at $2,913,000 after acquiring an additional 1,500,000 shares during the last quarter. Finally, Bain Capital Life Sciences Investors LLC increased its position in shares of X4 Pharmaceuticals by 6.0% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 16,915,784 shares of the company’s stock valued at $14,184,000 after acquiring an additional 955,196 shares during the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.